Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study

BACKGROUND: MET amplification or METex14 skipping mutations are uncommon oncogenic events in NSCLC patients. Clinicopathological characteristics, concurrent gene alterations, and prognosis of MET TKIs in these patients are yet to be elucidated. METHODS: We retrospectively analyzed the genomic profil...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Liu, Li, Kalyani, Farhin Shaheed, Yang, Haiyan, Zhou, Chunhua, Xiong, Yi, Zhu, Songlin, Yang, Nong, Qu, Jingjing
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264054/
https://ncbi.nlm.nih.gov/pubmed/34249687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.649766
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller